Rapid remission of life‐threatening chylo‐ascites with dabrafenib and trametinib combination in complex lymphatic anomaly with pathogenic somatic BRAF and PIK3CA co‐variation

Documenti analoghi

• BRAF/MEK inhibitors use to treat ventriculoperitoneal shunt‐associated ascites in pediatric low‐grade gliomas
  di: Nisreen Amayiri, et al.
  Pubblicazione: (2024)
• Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T‐lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia
  di: Wallace Bourgeois, et al.
  Pubblicazione: (2024)
• NRAS melanoma response to trametinib and azacitidine
  di: Shannon Wessel, et al.
  Pubblicazione: (2024)
• Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib
  di: Isaac Hauk, et al.
  Pubblicazione: (2024)
• Response to trametinib Monotherapy Without Hematopoietic Stem Cell Transplant in Juvenile Myelomonocytic Leukemia
  di: Rozalyn Chok, et al.
  Pubblicazione: (2026)